A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.

MLA

Kotecha, Ritesh R., et al. “A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.” European Urology Oncology, vol. 7, no. 4, Aug. 2024, pp. 804–11. EBSCOhost, https://doi.org/10.1016/j.euo.2023.10.017.

APA

Kotecha, R. R., Doshi, S. D., Knezevic, A., Chaim, J., Chen, Y., Jacobi, R., Zucker, M., Reznik, E., McHugh, D., Shah, N. J., Feld, E., Aggen, D. H., Rafelson, W., Xiao, H., Carlo, M. I., Feldman, D. R., Lee, C.-H., Motzer, R. J., & Voss, M. H. (2024). A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology, 7(4), 804–811. https://doi.org/10.1016/j.euo.2023.10.017

Chicago

Kotecha, Ritesh R, Sahil D Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, et al. 2024. “A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.” European Urology Oncology 7 (4): 804–11. doi:10.1016/j.euo.2023.10.017.